MCM
LRMR icon

Monimus Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Monimus Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-49,073
Closed -$159K – 69
2025
Q3 		$159K Sell
49,073
-97,211
-66% -$365K 0.1% 59
2025
Q2 		$423K Hold
146,284
– – 0.31% 51
2025
Q1 		$315K Buy
146,284
+99,184
+211% +$314K 0.27% 45
2024
Q4 		$182K Buy
+47,100
New +$311K 0.17% 50

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Monimus Capital Management's LRMR Position: Q4 2025 in Review

Monimus Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 49,073 shares — an estimated $159K sold.

Monimus Capital Management first reported a position in LRMR in Q4 2024 and held it in 4 quarters. The position peaked at $423K in Q2 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

  • Monimus Capital Management reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Monimus Capital Management sold 49,073 Larimar Therapeutics shares in Q4 2025, an estimated $159K.
  • Monimus Capital Management first reported a position in Larimar Therapeutics in Q4 2024 and held it in 4 quarters.
  • Monimus Capital Management's Larimar Therapeutics position peaked at $423K in Q2 2025.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Monimus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.